Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Treatment outcomes in a cohort of patients with chronic hepatitis B and human immunodeficiency virus co-infection in Mumbai, India.

Isaakidis P, Mansoor H, Zachariah R, Da Silva EA, Varghese B, Deshpande A, Dal Molin TA, Ladomirska J, Arnould L, Reid T.

Int Health. 2012 Dec;4(4):239-45. doi: 10.1016/j.inhe.2012.04.002.

PMID:
24029669
2.

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.

Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, Rozenbaum W, Le Teuff G, Trylesinski A, Piketty C; TECOVIR Study Group..

Hepatology. 2006 Mar;43(3):548-55.

PMID:
16496322
3.

Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.

Childs K, Joshi D, Byrne R, Bruce M, Carey I, Agarwal K, Taylor C.

AIDS. 2013 Jun 1;27(9):1443-8. doi: 10.1097/QAD.0b013e32836011c2.

PMID:
23435302
4.

Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.

Stephan C, Berger A, Carlebach A, Lutz T, Bickel M, Klauke S, Staszewski S, Stuermer M.

J Antimicrob Chemother. 2005 Dec;56(6):1087-93. Epub 2005 Nov 3.

PMID:
16269552
5.

Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.

Lacombe K, Gozlan J, Boelle PY, Serfaty L, Zoulim F, Valleron AJ, Girard PM.

AIDS. 2005 Jun 10;19(9):907-15.

PMID:
15905671
6.

[Epidemiological and clinical features of occult hepatitis B in HIV infection without antiretroviral treatment].

Zhang RF, Liu L, Zheng YF, Shen YZ, Chen J, Gu SM, Wang JR, Lu HZ.

Zhonghua Gan Zang Bing Za Zhi. 2013 Mar;21(3):189-91. Chinese.

PMID:
23967739
7.

Hepatitis B and HIV co-infection is still treated using lamivudine-only antiretroviral therapy combination in Uganda.

Ocama P, Seremba E, Apica B, Opio K.

Afr Health Sci. 2015 Jun;15(2):328-33. doi: 10.4314/ahs.v15i2.4.

8.

Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.

Lewin SR, Ribeiro RM, Avihingsanon A, Bowden S, Matthews G, Marks P, Locarnini SA, Ruxrungtham K, Perelson AS, Dore GJ.

Hepatology. 2009 Apr;49(4):1113-21. doi: 10.1002/hep.22754.

9.

Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.

Wesdorp DJ, Knoester M, Braat AE, Coenraad MJ, Vossen AC, Claas EC, van Hoek B.

J Clin Virol. 2013 Sep;58(1):67-73. doi: 10.1016/j.jcv.2013.06.035. Epub 2013 Jul 20.

10.

Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.

Boyd A, Maylin S, Gozlan J, Delaugerre C, Simon F, Girard PM, Lacombe K.

Liver Int. 2015 Mar;35(3):795-804. doi: 10.1111/liv.12521. Epub 2014 Mar 31.

PMID:
24606220
11.
12.

A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.

Yalçin K, Değertekin H, Kokoğlu OF, Ayaz C.

Turk J Gastroenterol. 2004 Mar;15(1):14-20.

13.

Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.

Kosi L, Reiberger T, Payer BA, Grabmeier-Pfistershammer K, Strassl R, Rieger A, Peck-Radosavljevic M.

J Viral Hepat. 2012 Nov;19(11):801-10. doi: 10.1111/j.1365-2893.2012.01601.x. Epub 2012 Mar 15.

PMID:
23043387
14.

Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.

Alvarez-Uria G, Ratcliffe L, Vilar J.

HIV Med. 2009 May;10(5):269-73. doi: 10.1111/j.1468-1293.2008.00683.x. Epub 2009 Feb 5.

15.

Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.

Boyd A, Gozlan J, Maylin S, Delaugerre C, Peytavin G, Girard PM, Zoulim F, Lacombe K.

Hepatology. 2014 Aug;60(2):497-507. doi: 10.1002/hep.27182. Epub 2014 Jun 20.

PMID:
24752996
16.

Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients.

Attia KA, Eholié S, Messou E, Danel C, Polneau S, Chenal H, Toni T, Mbamy M, Seyler C, Wakasugi N, N'dri-Yoman T, Anglaret X.

World J Hepatol. 2012 Jul 27;4(7):218-23. doi: 10.4254/wjh.v4.i7.218.

17.

Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients.

Boyd A, Piroth L, Maylin S, Maynard-Muet M, Lebossé F, Bouix C, Lascoux-Combe C, Mahjoub N, Girard PM, Delaugerre C, Carrat F, Lacombe K, Miailhes P.

J Viral Hepat. 2016 Dec;23(12):1017-1026. doi: 10.1111/jvh.12581. Epub 2016 Aug 3.

PMID:
27486094
18.

Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.

Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, Desmond PV, Roberts SK, Locarnini S, Bowden S, Angus PW.

Gut. 2011 Feb;60(2):247-54. doi: 10.1136/gut.2010.223206. Epub 2010 Oct 29.

PMID:
21036792
19.

Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients.

Maylin S, Boyd A, Lavocat F, Gozlan J, Lascoux-Combe C, Miailhes P, Lassel L, Delaugerre C, Girard PM, Zoulim F, Lacombe K.

AIDS. 2012 May 15;26(8):939-49. doi: 10.1097/QAD.0b013e328352224d.

PMID:
22333748
20.

Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.

Núñez M, Ramos B, Díaz-Pollán B, Camino N, Martín-Carbonero L, Barreiro P, González-Lahoz J, Soriano V.

AIDS Res Hum Retroviruses. 2006 Sep;22(9):842-8.

PMID:
16989608

Supplemental Content

Support Center